Ubix Therapeutics, Inc.

Korea Research Institute of Chemical Technology

Jung Min Ahn

Song Hee Lee

Je Ho Ryu

Ji Youn Park

Ho Hyun Lee

Sung Yun Cho

Hyun Jin Kim

Jae Du Ha

Jong Yeon Hwang

Chi Hoon Park

Pil Ho Kim

Ji Young Kim

Yu Ri Choi

Hanwool Kim

Mi Young Jang

Yae Jin Woo

Ye Seul Lim

Han Wool Kim

Hee Jung Moon

Beom Seon Suh

Sun Mi Yoo

The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof

The present disclosure provides a substituted piperidine compound of Chemical Formula 1, wherein X is CR, or a pharmaceutically acceptable salt thereof having activity of degrading androgen receptor (AR). The present disclosure also provides a composition comprising such a substituted piperidine compound or a pharmaceutically acceptable salt thereof. The present disclosure also provides a medical use of a substituted piperidine compound according to the present disclosure, a salt thereof, and a composition comprising the same for the treatment or prophylaxis of AR-related diseases. The present disclosure also provides a method for treating or preventing an AR-related disease comprising administering to a subject in need thereof an effective amount of a substituted piperidine compound according to the present disclosure, a salt thereof, or a composition comprising the same.

Substituted piperidines for androgen receptor degradation

Growing community of inventors

Incheon, South Korea

Jung Min Ahn